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ABSTRAK
Kemoprofilaksis malaria menggunakan meflokuin telah menjadi regimen standar WHO bagi anggota militer 
yang berada di daerah endemik dalam jangka waktu cukup panjang. Dalam laporan kasus ini disajikan kasus 
infeksi Plasmodium ovale pada anggota muda militer Indonesia yang telah mendapat profilaksis meflokuin 250 
mg/minggu selama satu tahun. Pasien tersebut mengalami demam mengigil yang tipikal setelah kembali dua 
minggu dari tugas di Kongo, Afrika Barat-Tengah. Diagnosis malaria ovale ditegakkan melalui pulasan darah 
tepi, dan ditemukan 35/250 parasit dalam lapang pandang kecil mikroskop. Kasus kegagalan profilaksis jangka 
panjang pada dasarnya jarang ditemui, mengingat meflokuin telah menjadi obat pencegahan malaria, bahkan 
untuk kasus Plasmodium multi-resisten. Diduga, stadium dorman dari Plasmodium ovale, resistensi golongan 
obat kuinolin, dan efikasi meflokuin menjadi penyebab terjadinya fenomena tersebut.
Kata kunci: plasmodium ovale, meflokuin, profilaksis malaria, malaria tertiana.
ABSTRACT
Malaria chemoprevention using mefloquine has become the WHO standard regimen for military personnel 
who stay in the endemic area for an extended period of time. We reported a case of Plasmodium ovale infection 
in a young Indonesian Soldier following one year mefloquine prophylaxis 250 mg weekly. Typical fever and chills 
were experienced two weeks after returning from one year duty in Congo, West-Central Africa. The diagnosis of 
ovale malaria was made by peripheral blood smear, and 35/250 parasites in small microscopic view was found. 
Then, he recovered after dihydroartemisin and primaquine combination therapy. This was an unusual case of 
long-term prophylaxis failure since mefloquine has been recognized as the agent for malaria prevention, even 
multi-drug-resistance Plasmodium. Dormant stage of Plasmodium ovale, quinoline-resistance potential, and 
the efficacy of mefloquine itself are discussed as the cause of that phenomenon.
Keywords: plasmodium ovale, mefloquine, malaria prophylaxis, tertiana malaria.
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INTRODUCTION
Chemoprophylaxis is one of the main 
approaches to prevent malaria worldwide.1 It 
aims to prevent the occurrence of the symptoms 
of malaria since no available drug can clearly 
destroy the sporozoites, which remain in the 
bloodstream in a short time before entering the 
liver. The most popular chemoprophylaxis are 
mefloquine and doxycycline, suppressive agents 
that kill schizonts in the bloodstream; however, 
they do not act on the parasite in the liver.2
M e f l o q u i n e  i s  w e l l - k n o w n  a s  a 
chemoprophylaxis agent for more than twenty 
years. It is claimed as an effective schizonside 
of all malaria species, including the newer 
Plasmodium knowlesi, which prevents the 
chloroquine-resistant Plasmodium falciparum 
(CRPF). Despite its benefit, this drug has 
produced a long debate among stakeholders 
worldwide due to its adverse effects, which 
are mainly psychosis, suicidal behaviour, or 
hallucination.3,4 This issue rapidly raised among 
military personnel who take mefloquine for a 
longer time as compared to usual travelers or 
visitors.5
We reported a case of Plasmodium ovale 
infection in a young Indonesian soldier who had 
taken mefloquine prophylaxis for one year due 
to his service in Congo, Africa. Since P. ovale 
infection is mild and among the most infrequently 
reported cases of malaria worldwide, therefore, 
the efficacy of mefloquine to prevent this 
infection has brought out a big question mark.6 
While numerous papers have reviewed about its 
adverse events, there are limited data available 
about mefloquine efficacy to prevent P. ovale. 
Several potential mechanisms of this prophylaxis 
failure are also interesting to be discussed further.
CASE ILUSTRATION
A 22-year-old Indonesia soldier came with 
a complaint of high fever and chills, which had 
lasted for four days. He had just come back from 
United Nations service in Congo, Africa, three 
weeks before. Fever was followed by nausea 
and vomiting. The patient and his colleagues 
in Indonesia’s military personnel attributable to 
service in Congo have already taken mefloquine 
dosage 250 mg weekly for one year due to 
this assignment. They had routinely taken the 
medication on a regular basis, as declared in the 
prerequisite checklist card prior to their duty. 
No symptom of insomnia, depression, anxiety, 
or significant neurological events was found. 
No history of prior malaria was recorded in this 
patient.
There was no skin rash nor sign of bleeding. 
His liver was mildly enlarged, but no splenomegaly 
was palpated. His laboratory examination revealed 
the following: anemia 10.8 g/dL with normocytic 
normochromic morphology, mild leucopenia 
4,600/µL, and thrombo-cytopenia 105,000/µL. 
There was a little increase of AST (56 U/L) and 
ALT (42 U/L), but no abnormality was found 
in ureum, creatinine, blood glucose level, and 
electrolytes levels. Other possible infections 
were excluded by normal urinalysis and chest 
X-ray, negative Tubex® test, leptospira IgM, and 
normal procalcitonin levels. Dengue IgM and 
IgG antibody were also checked following the 
sixth day of fever, and negative result was found. 
Blood cultures did not yield any result. Rapid 
diagnostic test was negative for both HRP2 (for 
P. falciparum) and pLDH (for P. vivax); however, 
we determined positive P. ovale infection under 
the light microscopy with Giemsa’s staining 
(Figure 1). He had 35/250 paracites under small 
microscopic view.
Figure 1. Giemsa-stained thin blood films of the patient 
(viewed under 1000x magnification).
(a) Gametocyte; (b) Rings in fimbriated red blood cells; (c) 
Trophozoites have sturdy cytoplasm, large chromatin dot, 
showing Schüffner dots.
61
Vol 51 • Number 1 • January 2019                    Plasmodium ovale infection after one year Mefloquine prophylaxis
The pat ient  was then treated with 
dihydroartemisinin for 3 days and primaquine 
for 14 days. The parasites were shown negative 
since the third day following treatments.
DISCUSSION
Although most malaria cases are dominated 
by P. falciparum and P. vivax, for certain 
reasons‒ in this case, mandatory duty for 
military personnel ‒ chemoprophylaxis for 
other species including P. ovale is warranted.5 
French military personnel who took doxycycline 
chemoprophylaxis experienced an increase of P. 
ovale infection after returning from Ivory Coast, 
West Africa, between 2002 and 2007; within the 
same period, they experienced a lower incidence 
rate of P. falciparum infection.7 This phenomenon 
may imply the lower effectiveness of doxycycline 
on P. ovale than on P. falciparum; despite other 
possibilities of changes in local transmission.
The prevalence of P. ovale infection in West 
and Central Africa is around 10%, which is 
significantly higher compared to other regions 
in of the world (ranged 2-5%).6,8 With the 
incubation period of 10-17 days, this type of 
malaria usually causes mild disease with low 
parasetemia. Only a few of publications reported 
severe and complicated cases due to P. ovale.9,10 
This case illustration raised several questions 
about P. ovale infection after one year mefloquine 
prophylaxis. First, the influence of dormant stage 
of P. ovale during exposure period in Africa 
that might relapse later when coming/returning 
back to Indonesia. Second, the presumption 
of quinoline resistance in P. ovale could not 
be excluded yet. And the last, it is rationale to 
question the efficacy of mefloquine in minor 
species (ovale and malaria) that is limited in 
publication or clinical trial.
Dormant Stage of P. ovale and Clinical 
Implications
 Evidences showed that P. ovale and P. vivax 
are associated with the relapse of malaria cases, 
which is caused from quiescent intracellular 
hepatic parasite stadium called hypozoites. 
Relapse cases are different with recrudescence, 
that originates from the circulation of parasite 
blood stages which do not cause fever before 
a certain level of parasitemia is reached. 
Recrudescence typically occurs due to P. 
falciparum, P. knowlesi, and P. malariae 
infections. True relapses, on the other hand, 
occur most frequently in P. vivax, less frequently 
in P. ovale and P. malariae, but have never 
been documented so far in P. falciparum and P. 
knowlesi.11,12
According to Richter, et al12, only 5 of 
240 patients of P. ovale infections, in which 
primaquine was not given, suffered a relapse. 
In contrast, several relapses despite primaquine 
prophylaxis have been described. This could 
be explained by insufficient resorption of 
primaquine, or the presence of quiescent 
extrahepatic plasmodial development stages that 
is insensitive to primaquine.
Quinoline-Resistant P. ovale
There are limited reports on drug resistance 
in P. ovale. However, the high burden of 
quinoline-resistance P. falciparum also raises 
arguments that similar phenomena might 
possibly happen in minor Plasmodium. These 
arguments are supported by several severe 
and complicated malaria case reports such as 
acute respiratory distress syndrome, end-stage 
renal failure, or splenic rupture or infarction 
following P. ovale infection.13,14 Lau, et al15 has 
reported a fatal P. ovale case in a 59-year-old 
male in Victoria Island, Nigeria, after 6 months 
of mefloquine. However, the pathophysiology 
and risk factors for its severe infection have not 
yet fully established.
Using in vitro and in vivo studies, Siswantoro 
H, et al16 described the potential of quinoline 
resistance (chloroquine and mefloquine) in P. 
ovale and P. malariae in malaria subjects in 
Papua, Indonesia. However, subjects infected 
by P. ovale responded rapidly to treatments; 
all subjects were afebrile within 24 hours and 
aparasitemic within 48 hours.16
Efficacy of Mefloquine in P. ovale
Mefloquine was first developed in 1970s 
by US military’s Walter Reed Army Institute of 
Research (WRAIR) in response to the increasing 
number of chloroquine-resistant P. falciparum in 
Southeast Asia. It was licensed and introduced 
to civilian market, targeted mainly on travelers, 
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in late 1980s and soon became widely used as 
chemoprophylaxis.17 This drug is still used by 
several military forces for many years, such as 
US Soldier until 2009, and to date in Canada, 
Australia, UK, as well as Indonesia.4,5,18
Mefloquine is a fluorinated 4-quinoline 
methanol compound, and its parasiticidal 
action is similar to that of quinine.19 In addition 
to antimalarial prophylaxis, this drug is also 
widely used to treat uncomplicated multi-drug-
resistance falciparum malaria in combination 
with artesunate. As an anti-falciparum agent, a 
single dose alone could be practically used, but 
this leads more rapidly to resistance, thus it is no 
longer recommended.1,17
 No literature has reported the real number 
of efficacy of mefloquine as malaria prevention. 
However, Lee, et al20 reported a severe P. ovale 
infection in a 31-year-old female after 10 months 
of mefloquine prophylaxis in Ghana (parasitemia 
0.1%). Surprisingly, the subject fully recovered 
with chloroquine and primaquine treatment (the 
same types of drugs).20
CONCLUSION
A case of P. ovale infection persisting after 
one year of mefloquine prophylaxis was reported. 
Several reasons may explain this phenomenon, 
however, it is still required to refining the benefit 
and risk of mefloquine as the chemoprophylaxis 
in the military.
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